126 related articles for article (PubMed ID: 38128180)
21. Pharmacokinetics-derived absorbed components responsible for Guizhi-Fuling capsule target PI3K/Akt-Erk to exert an anti-dysmenorrhea effect.
Zhao Q; Cheng J; Bian X; Wang C; Xu Y; Ding H; Ren H; Zhang Y; Xu M; Shan C; Yan H; Duan J; Qian D; Huang X
J Ethnopharmacol; 2022 Oct; 297():115525. PubMed ID: 35811027
[TBL] [Abstract][Full Text] [Related]
22. [Quality evaluation of guizhi fuling capsule using self-control method of reference Chinese medicine preparation].
Geng T; Zhang ZJ; Li YJ; Ding G; Bi YA; Wang ZZ; Xiao W
Zhongguo Zhong Yao Za Zhi; 2014 Nov; 39(21):4127-32. PubMed ID: 25775780
[TBL] [Abstract][Full Text] [Related]
23. A traditional gynecological medicine inhibits ovarian cancer progression and eliminates cancer stem cells via the LRPPRC-OXPHOS axis.
Jiang R; Chen Z; Ni M; Li X; Ying H; Fen J; Wan D; Peng C; Zhou W; Gu L
J Transl Med; 2023 Jul; 21(1):504. PubMed ID: 37496051
[TBL] [Abstract][Full Text] [Related]
24. Long non-coding RNA THOR promotes ovarian Cancer cells progression via IL-6/STAT3 pathway.
Ge J; Han T; Shan L; Na J; Li Y; Wang J
J Ovarian Res; 2020 Jun; 13(1):72. PubMed ID: 32552789
[TBL] [Abstract][Full Text] [Related]
25. ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1.
Li YK; Gao AB; Zeng T; Liu D; Zhang QF; Ran XM; Tang ZZ; Li Y; Liu J; Zhang T; Shi GQ; Zhou WC; Zou WD; Peng J; Zhang J; Li H; Zou J
J Transl Med; 2024 Jan; 22(1):46. PubMed ID: 38212795
[TBL] [Abstract][Full Text] [Related]
26. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3).
Kandala PK; Srivastava SK
BMC Med; 2012 Jan; 10():9. PubMed ID: 22280969
[TBL] [Abstract][Full Text] [Related]
27. Paraoxonase 2 overexpression inhibits tumor development in a mouse model of ovarian cancer.
Devarajan A; Su F; Grijalva V; Yalamanchi M; Yalamanchi A; Gao F; Trost H; Nwokedi J; Farias-Eisner G; Farias-Eisner R; Fogelman AM; Reddy ST
Cell Death Dis; 2018 Mar; 9(3):392. PubMed ID: 29531225
[TBL] [Abstract][Full Text] [Related]
28. The Multiple Pharmacologic Functions and Mechanisms of Action of Guizhi Fuling Formulation.
Gao J; Yang J; Lu Z; Dong X; Xu Y
Evid Based Complement Alternat Med; 2022; 2022():6813421. PubMed ID: 35529925
[TBL] [Abstract][Full Text] [Related]
29. Syringic acid regulates suppression of the STAT3/JNK/AKT pathway via inhibition of human ovarian teratoma cancer cell (PA-1) growth-in vitro study.
Yang L; Qu C; Jin J; Yang H; Pei L
J Biochem Mol Toxicol; 2021 Jun; 35(6):1-9. PubMed ID: 33759321
[TBL] [Abstract][Full Text] [Related]
30. PDZ and LIM domain protein 4 suppresses the growth and invasion of ovarian cancer cells via inactivation of STAT3 signaling.
Jia Y; Shi H; Cao Y; Feng W; Li M; Li X
Life Sci; 2019 Sep; 233():116715. PubMed ID: 31376371
[TBL] [Abstract][Full Text] [Related]
31. Integrated identification, qualification and quantification strategy for pharmacokinetic profile study of Guizhi Fuling capsule in healthy volunteers.
Zhong YX; Jin XL; Gu SY; Peng Y; Zhang KR; Ou-Yang BC; Wang Y; Xiao W; Wang ZZ; Aa JY; Wang GJ; Sun JG
Sci Rep; 2016 Aug; 6():31364. PubMed ID: 27527657
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of Heat Shock Protein 90 suppresses TWIST1 Transcription.
Chong KY; Kang M; Garofalo F; Ueno D; Liang H; Cady S; Madarikan O; Pitruzzello N; Tsai CH; Hartwich TMP; Shuch BM; Yang-Hartwich Y
Mol Pharmacol; 2019 Aug; 96(2):168-179. PubMed ID: 31175180
[TBL] [Abstract][Full Text] [Related]
33. Potential Mechanisms of Guizhi Fuling Wan in Treating Endometriosis: An Analysis Based on TCMSP and DisGeNET Databases.
Yee JL; Huang CY; Yu YC; Huang SJ
J Ethnopharmacol; 2024 Jul; 329():118190. PubMed ID: 38614264
[TBL] [Abstract][Full Text] [Related]
34. Triptolide inhibits JAK2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatin‑resistant SKOV3/DDP ovarian cancer cells.
Zhong Y; Le F; Cheng J; Luo C; Zhang X; Wu X; Xu F; Zuo Q; Tan B
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760192
[TBL] [Abstract][Full Text] [Related]
35. Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis.
Wei X; Liu Y; Gong C; Ji T; Zhou X; Zhang T; Wan D; Xu S; Jin P; Yang X; Li X; Ma D; Yang Z; Gao Q
Anticancer Agents Med Chem; 2017; 17(8):1093-1101. PubMed ID: 28002999
[TBL] [Abstract][Full Text] [Related]
36. JS-K, a nitric oxide donor, induces autophagy as a complementary mechanism inhibiting ovarian cancer.
Liu B; Huang X; Li Y; Liao W; Li M; Liu Y; He R; Feng D; Zhu R; Kurihara H
BMC Cancer; 2019 Jul; 19(1):645. PubMed ID: 31262254
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of STAT3 signaling as critical molecular event in resveratrol-suppressed ovarian cancer cells.
Zhong LX; Li H; Wu ML; Liu XY; Zhong MJ; Chen XY; Liu J; Zhang Y
J Ovarian Res; 2015 Apr; 8():25. PubMed ID: 25896424
[TBL] [Abstract][Full Text] [Related]
38. Role of Jagged1/STAT3 signalling in platinum-resistant ovarian cancer.
Yang J; Xing H; Lu D; Wang J; Li B; Tang J; Gu F; Hong L
J Cell Mol Med; 2019 Jun; 23(6):4005-4018. PubMed ID: 30993885
[TBL] [Abstract][Full Text] [Related]
39. Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer.
Nakamura H; Nagasaka K; Kawana K; Taguchi A; Uehara Y; Yoshida M; Sato M; Nishida H; Fujimoto A; Inoue T; Adachi K; Nagamatsu T; Arimoto T; Oda K; Osuga Y; Fujii T
BMC Cancer; 2016 Nov; 16(1):897. PubMed ID: 27855669
[TBL] [Abstract][Full Text] [Related]
40. The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer.
Chen MW; Yang ST; Chien MH; Hua KT; Wu CJ; Hsiao SM; Lin H; Hsiao M; Su JL; Wei LH
Cancer Res; 2017 Apr; 77(8):1955-1967. PubMed ID: 28209618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
